ABT vs LLY
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
Abbott Laboratories exhibits strong fundamental health with a Piotroski F-Score of 7/9 and a very conservative debt-to-equity ratio of 0.27. However, the stock is currently in a severe technical downtrend (0/100) and trades at a significant premium to its Graham Number ($50.12) and Intrinsic Value ($26.04). While analyst targets suggest significant upside to $131.44, the combination of bearish insider selling and poor short-term price performance offsets the strong balance sheet.
LLY shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
Compare Another Pair
Related Comparisons
ABT vs LLY: Head-to-Head Comparison
This page compares Abbott Laboratories (ABT) and Eli Lilly and Company (LLY) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.